Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19.
Antivir Ther
; 25(4): 233-239, 2020.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1256707
ABSTRACT
Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high infectivity. The globally pandemic outbreak suggests that COVID-19 is highly infectious and difficult to control. A dual-combination of ribavirin and interferon-α has been the widely used regimen for the treatment of this disease in China. However, due to the varying results of treatment with these drugs, a novel antiviral combination therapy is urgently needed. This case reports the usage of lopinavir/ritonavir-based combination antiviral regimen for a patient with SARS-CoV-2 infection.
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
SARS-CoV-2
/
Tratamiento Farmacológico de COVID-19
Tipo de estudio:
Reporte de caso
/
Estudio observacional
/
Estudio pronóstico
Límite:
Adulto
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Antivir Ther
Asunto de la revista:
Terapia por drogas
/
Virología
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
Imp3362
Similares
MEDLINE
...
LILACS
LIS